KYTX — Kyverna Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1994702 ·
Last close
$8.61
Market Cap
$523.45M
52W High
$11.62
52W Low
$7.34
ADV30
1,184,841
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -41,367,000 | -39,728,000 | 257,024,000 | 32,194,000 | 61,444,000 |
| Dec 2025 | 0 | — | -39,282,000 | -37,804,000 | 293,826,000 | 124,093,000 | 61,550,000 |
| Sep 2025 | 0 | — | -38,727,000 | -36,787,000 | 187,156,000 | 34,164,000 | 35,210,000 |
| Jun 2025 | 0 | — | -44,410,000 | -42,081,000 | 226,508,000 | 53,440,000 | 42,131,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-153,712,000
Investing CF
$40,015,000
Financing CF
$141,168,000
CapEx
$-1,563,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.65
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-424,827,000
Inventory
—
Receivables
—
ST Investments
$155,160,000
EBIT TTM
$-160,817,000
Pretax Income TTM
$-161,307,000
Interest Exp TTM
$490,000
Analysts
5
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,827,000 | -161,307,000 | 293,826,000 | 61,550,000 | — | -153,712,000 |
| Dec 2024 | 0 | -142,604,000 | -127,477,000 | 304,645,000 | 38,058,000 | — | -114,250,000 |
| Dec 2023 | 0 | -62,406,000 | -60,366,000 | 75,195,000 | 206,592,000 | — | -52,410,000 |
| Dec 2022 | 7,025,000 | -29,384,000 | -28,893,000 | 66,924,000 | 140,921,000 | — | -36,113,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.95
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| EIKN | Eikon Therapeutics, Inc. | $535.97M | $9.90 | — |
| PRME | Prime Medicine, Inc. | $536.43M | $2.97 | — |
| AGMB | Agomab Therapeutics NV | $544.19M | $11.05 | — |
| TECX | Tectonic Therapeutic, Inc. | $565.89M | $29.99 | — |
| VALN | Valneva SE | $573.68M | $6.05 | — |
News headlines (Yahoo Finance, 1h cache)
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
2026-05-18 12:00 · Yahoo
KYV-101 Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
2026-05-15 09:04 · Yahoo
Kyverna Therapeutics to Present at Upcoming Investor Conferences
2026-05-14 12:00 · Yahoo
Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B
2026-05-13 10:27 · Yahoo
Kyverna Therapeutics Announces Initiation of Rolling SPS BLA Submission and Reports First Quarter 2026 Financial Results
2026-05-12 20:02 · Yahoo
Kyverna Therapeutics Appoints Nadia Dac, Seasoned Commercial Leader in Neurology and Rare Disease, as Chief Commercial Officer
2026-05-04 12:00 · Yahoo
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
2026-04-25 12:31 · Yahoo
Kyverna Presents Registrational Trial Primary Analysis for Miv-cel in Stiff Person Syndrome Demonstrating Statistically Significant, Durable Clinical Benefit Across All Endpoints in an Oral, Late-Brea
2026-04-21 22:45 · Yahoo
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
2026-04-20 12:00 · Yahoo
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
2026-04-09 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.